Premium
P4‐610: PSYCHOMETRIC FINDINGS RELATED TO THE PRESENCE OF AMYLOID IN SYMPTOMATIC AND ASYMPTOMATIC SUBJECTS
Author(s) -
Voccia Pamela,
Kruczek Katherine,
Cody Jennifer,
Paiano Ruth,
Cohen Michelle
Publication year - 2019
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2019.08.158
Subject(s) - asymptomatic , amyloid (mycology) , medicine , amyloidosis , cognition , gastroenterology , psychology , pathology , psychiatry
was computed with the scores of the CERAD constructional praxis recall and the Rey Complex Figure immediate recall. Cortical amyloid accumulation was measured using PiB PET, and regional tau accumulation in the entorhinal cortex (EC), inferior temporal cortex (IT) and precuneus (PCu) was measured using Flortaucipir F18 PET. Results: The mean age of carriers was 35 years, approximately 9 years younger than the expected onset of clinical symptoms. There were no differences between groups in VM performance (p1⁄4 0.82). Compared with non-carriers, mutation carriers had elevated levels of cortical amyloid (p < 0.001) and tau (EC: p < 0.001, IT: p 1⁄4 0.02, PCu: p < 0.01). In mutation carriers, greater amyloid burden was associated with worse VM performance (r 1⁄4 -0.53, p 1⁄4 0.02). In addition, higher levels of tau accumulation were associated with lower VM performance (EC: r 1⁄4 -0.65, p 1⁄4 0.002; IT: r 1⁄4 -0.51, p 1⁄4 0.02; PCu: r 1⁄4 -0.64, p 1⁄4 0.003). No such relationships were significant in non-carriers. Conclusions: Preliminary findings suggest that subtle changes in VM performance may have a negative association with markers of AD pathology in preclinical ADAD, several years before symptom onset. Further investigation with larger samples is needed to confirm present findings, and to examine the potential usefulness of these cognitive measures for identifying those individuals at high risk to develop dementia later in life.